These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

571 related items for PubMed ID: 23733802

  • 21. Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
    Weidman DR, Pole JD, Bouffet E, Taylor MD, Bartels U.
    Pediatr Blood Cancer; 2015 Oct; 62(10):1754-60. PubMed ID: 25929843
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
    Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S.
    Lancet; 2013 Jan 12; 381(9861):125-32. PubMed ID: 23158522
    [Abstract] [Full Text] [Related]

  • 23. Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option?
    Wiegand G, May TW, Ostertag P, Boor R, Stephani U, Franz DN.
    Eur J Paediatr Neurol; 2013 Nov 12; 17(6):631-8. PubMed ID: 23845174
    [Abstract] [Full Text] [Related]

  • 24. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.
    Somers MJ, Paul E.
    J Clin Pharmacol; 2015 Apr 12; 55(4):368-76. PubMed ID: 25402866
    [Abstract] [Full Text] [Related]

  • 25. Everolimus tablets for patients with subependymal giant cell astrocytoma.
    Turner SG, Peters KB, Vredenburgh JJ, Desjardins A, Friedman HS, Reardon DA.
    Expert Opin Pharmacother; 2011 Oct 12; 12(14):2265-9. PubMed ID: 21806479
    [Abstract] [Full Text] [Related]

  • 26. Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC).
    Brakemeier S, Vogt L, Adams L, Zukunft B, Diederichs G, Hamm B, Budde K, Makowski MR.
    PLoS One; 2017 Oct 12; 12(12):e0189132. PubMed ID: 29232371
    [Abstract] [Full Text] [Related]

  • 27. Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients.
    Brakemeier S, Bachmann F, Budde K.
    Pediatr Nephrol; 2017 Jul 12; 32(7):1137-1144. PubMed ID: 27585680
    [Abstract] [Full Text] [Related]

  • 28. Everolimus alters white matter diffusion in tuberous sclerosis complex.
    Tillema JM, Leach JL, Krueger DA, Franz DN.
    Neurology; 2012 Feb 21; 78(8):526-31. PubMed ID: 22262746
    [Abstract] [Full Text] [Related]

  • 29. Role of mTOR inhibition in the treatment of patients with renal angiomyolipomas.
    Coombs EJ.
    J Am Assoc Nurse Pract; 2013 Nov 21; 25(11):588-96. PubMed ID: 24170533
    [Abstract] [Full Text] [Related]

  • 30. Complications of mammalian target of rapamycin inhibitor anticancer treatment among patients with tuberous sclerosis complex are common and occasionally life-threatening.
    Trelinska J, Dachowska I, Kotulska K, Fendler W, Jozwiak S, Mlynarski W.
    Anticancer Drugs; 2015 Apr 21; 26(4):437-42. PubMed ID: 25719621
    [Abstract] [Full Text] [Related]

  • 31. Systemic effects of treatment with mTOR inhibitors in tuberous sclerosis complex: a comprehensive review.
    Sadowski K, Kotulska K, Schwartz RA, Jóźwiak S.
    J Eur Acad Dermatol Venereol; 2016 Apr 21; 30(4):586-94. PubMed ID: 26403211
    [Abstract] [Full Text] [Related]

  • 32. Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition.
    Budde K, Gaedeke J.
    Am J Kidney Dis; 2012 Feb 21; 59(2):276-83. PubMed ID: 22130643
    [Abstract] [Full Text] [Related]

  • 33. Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex.
    Palavra F, Robalo C, Reis F.
    Oxid Med Cell Longev; 2017 Feb 21; 2017():9820181. PubMed ID: 28386314
    [Abstract] [Full Text] [Related]

  • 34. The efficacy of cannabidiol on renal angiomyolipoma and subependymal giant cell tumor volume in tuberous sclerosis complex.
    Barnett JR, Grinspoon RA, Harisinghani M, Caruso PA, Thiele EA.
    J Clin Neurosci; 2020 Jul 21; 77():85-88. PubMed ID: 32409220
    [Abstract] [Full Text] [Related]

  • 35. mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders.
    Franz DN, Capal JK.
    Orphanet J Rare Dis; 2017 Mar 14; 12(1):51. PubMed ID: 28288694
    [Abstract] [Full Text] [Related]

  • 36. The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.
    Curatolo P, Bjørnvold M, Dill PE, Ferreira JC, Feucht M, Hertzberg C, Jansen A, Jóźwiak S, Kingswood JC, Kotulska K, Macaya A, Moavero R, Nabbout R, Zonnenberg BA.
    Drugs; 2016 Apr 14; 76(5):551-65. PubMed ID: 26927950
    [Abstract] [Full Text] [Related]

  • 37. Treatment of tuberous sclerosis complex manifestations in children with mTOR inhibitors.
    Yeşil Ş, Kurucu B, Hamamcı MB, Yılmaz Ş, Şahin G.
    Childs Nerv Syst; 2024 Mar 14; 40(3):831-837. PubMed ID: 37947859
    [Abstract] [Full Text] [Related]

  • 38. The Efficacy of Everolimus for Facial Angiofibromas in Tuberous Sclerosis Complex Patients Treated for Renal Angiomyolipoma/Subependymal Giant Cell Astrocytoma.
    Wei CC, Hsiao YP, Gau SY, Wu YT, Wu CT, Wu MH, Tsai JD.
    Dermatology; 2021 Mar 14; 237(3):444-449. PubMed ID: 33032292
    [Abstract] [Full Text] [Related]

  • 39. The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1.
    Kingswood JC, Jozwiak S, Belousova ED, Frost MD, Kuperman RA, Bebin EM, Korf BR, Flamini JR, Kohrman MH, Sparagana SP, Wu JY, Brechenmacher T, Stein K, Berkowitz N, Bissler JJ, Franz DN.
    Nephrol Dial Transplant; 2014 Jun 14; 29(6):1203-10. PubMed ID: 24729041
    [Abstract] [Full Text] [Related]

  • 40. Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases.
    Lebwohl D, Anak O, Sahmoud T, Klimovsky J, Elmroth I, Haas T, Posluszny J, Saletan S, Berg W.
    Ann N Y Acad Sci; 2013 Jul 14; 1291():14-32. PubMed ID: 23659703
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.